A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

The Identification of the SIRT1 Activator SRT2104 as a Clinical Candidate

(2013) Pui Ng et al.   Letters in Drug Design & Discovery

Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man

(2012) Ethan Hoffmann et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis

(2012) Mayte Suárez-Fariñas et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the “Core” Pathogenesis of Disease

(2012) Suyan Tian et al.   PLoS One

Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis

(2010) Lisa C. Zaba et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis

(2010) Andrea Chiricozzi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Sirtuins — novel therapeutic targets to treat age-associated diseases

(2008) Siva Lavu et al.   NATURE REVIEWS DRUG DISCOVERY